Devoted To a Healthier Future
We are dedicated to identifying novel molecular and cellular
mechanisms that regulate tumor development and metastasis
A Promising Pipeline for Tomorrow's Pharmaceuticals
Biokine Home PageAmir Caspi2021-04-20T15:49:35+02:00
Targeting Tumor Microenvironment
The Biokine Story
Biokine Therapeutics is a private biopharmaceutical company founded in 2000. It’s leading product, BKT140/BL8040, is currently in Phase III for Stem Cell Mobilization Phase II for Leukemia, and Phase I/II for Immunotherapy for cancer together with immune check point inhibitor Pembrolizumab (Keytruda, Merck) and Atezolizumab (Tecentriq, Genentech/Roche). BL8040 was licensed to BiolineRx and is being developed in the clinic together with BiolineRx Ltd. (NASDAQ:BLRX). Biokine has developed a suite of unique technologies to target cancer and is conducting advanced preclinical research on two novel drug candidates discovered in-house. BKT130 is a novel antibody that targets a unique panel of chemokines that shape the tumor microenvironment. BKT130 is developed as a novel Immune checkpoint inhibitor for the treatment of cancer. BKT300 is a novel synthetic small molecule which inhibits selectively tumor growth and metastasis.
The mission of Biokine is devoted to identifying novel molecular and cellular mechanisms that regulate tumor development and metastasis and to develop novel therapeutics against these devastating diseases.
According to estimates from the International Agency for Research on Cancer (IARC), there were 12.7 million new cancer cases in 2008 worldwide,of which 5.6 million occurred in economically developed countries and 7.1 million in economically developing countries. The corresponding estimates for total cancer deaths in 2008 were 7.6 million (about 21,000 cancer deaths a day), 2.8 million in economically developed countries and 4.8 million in economically developing countries. By 2030, the global burden is expected to grow to 21.4 million new cancer cases and 13.2 million cancer deaths simply due to the growth and aging of the population, as well as reductions in childhood mortality and deaths from infectious diseases in developing countries.
In 2014, there will be an estimated 1,665,540 new cancer cases diagnosed and 585,720 cancer deaths in the US. Cancer remains the second most common cause of death in the US, accounting for nearly 1 of every 4 deaths.
Global Cancer Facts & Figures www.cancer.org
Amir Caspi2020-12-08T22:34:55+02:00October 30th, 2020|Comments Off on BioLineRx Announces Positive Results from Interim Analysis of GENESIS Phase 3 Trial of Motixafortide (BL-8040) in Stem Cell Mobilization.
Amir Caspi2021-06-01T18:22:50+02:00February 27th, 2020|Comments Off on BioLineRx Announces Notice of Allowance from USPTO for Patent Covering Motixafortide (BL-8040) in Combination With Anti-PD-1 for the Treatment of Any Type of Cancer